NEW YORK, Oct. 8, 2019 /PRNewswire/ —
Church & Dwight Co. (CHD)
Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations of “significant concerns” that CHD’s “strategy has pivoted towards extreme financial engineering, aggressive accounting, and managerial self-enrichment practices.”
If you are a CHD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Fibrocell Science, Inc. (FCSC)
Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Fibrocell to Castle Creek Pharmaceutical Holdings, Inc for $3.00 per share.
If you are a FCSC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
MacroGenics, Inc. (MGNX)
Lifshitz & Miller announces investigation of possible securities laws violations in connection with the American Society of Clinical Oncologists abstract of MacroGenics’ Phase III SOPHIA study of margetuximab, disclosing that the October 2018 PFS analysis resulted in a 0.9 month improvement.
If you are a MGNX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
MINDBODY, Inc. (MB)
Lifshitz & Miller announces investigation of possible securities laws violations in connection with allegations that MINDBODY depressed the value of MB’s stock directly preceding the merger offer by Vista.
If you are a MB investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
PaySign, Inc. (PAYS)
Lifshitz & Miller announces investigation of possible securities laws violations in connection with PaySign lowering its fiscal 2019 revenue guidance to a range of $35–$37 million, citing delays in onboarding of new plasma industry programs.
If you are a PAYS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Zebra Technologies Corporation (ZBRA)
Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Zebra schemed to conceal the complications associated with the flawed integration of Motorola and the significant costs associated with remedying them.
If you are a ZBRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Zynerbia Pharmaceuticals (ZYNE)
Lifshitz & Miller announces investigation into possible laws violations in connection with Zynerbia’s announcement that the results from its open-label Phase 2 BELIEVE 1 clinical trials evaluating topical gel Zygel revealed that the rate of treatment-emerged adverse events was 96% and that “two [serious adverse events] were determined to be possibly related to treatment.
If you are a ZYNE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
ATTORNEY ADVERTISING.© 2019 Lifshitz & Miller LLP. The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: [email protected]
SOURCE Lifshitz & Miller Law Firm